Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HaleonHLN +0.52%70 Buyback Yield % is 2.06 as of Jul. 15, 2026, which is 9% above its 10-year median of 1.89. GuruFocus rates HLN with a GF Score™ of 70/100 and a GF Value™ of $9.80 (Fairly Valued). The stock has 3 warning signs investors should review. Among 290 Drug Manufacturers companies, Haleon ranks better than 90.34% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for Haleon's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HLN vs ZTS, UTHR, VTRS: Buyback Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Haleon's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Haleon Buyback Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Haleon's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Haleon's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Haleon (HLN) has a Buyback Yield % of 2.06 as of Jul. 15, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Haleon and its competitors. This is near median its historical median of 1.89. Over the past decade, Haleon's Buyback Yield % has ranged from 1.08 to 2.06. According to the industry distribution chart, Haleon ranks #28 out of 290 companies in the Drug Manufacturers industry, placing it in the top 9.7%.
Is Haleon's Buyback Yield % too high?
Haleon's current Buyback Yield % of 2.06 is near median its 10-year median of 1.89. Over the past 10 years, this metric has ranged from a low of 1.08 to a high of 2.06. Based on the distribution chart, Haleon ranks #28 out of 290 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Haleon has a GF Score™ of 70/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Haleon's Buyback Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Haleon ranks #28 out of 290 companies for Buyback Yield %. This places Haleon in the top 10% of its industry — outperforming the majority of peers. Historically, Haleon's own Buyback Yield % has ranged from 1.08 to 2.06 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Drug Manufacturers company?
A good Buyback Yield % depends on the Drug Manufacturers industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Haleon and its competitors. Haleon's current Buyback Yield % is 2.06, which is near median its own 10-year median of 1.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Haleon stock overvalued right now?
Based on GuruFocus' analysis, Haleon (HLN) is currently considered Fairly Valued. The stock's GF Value™ is $9.80, compared to a current price of $9.75 — trading 0.5% below its estimated fair value. The current Buyback Yield % is 2.06, which is near median its 10-year median of 1.89. Haleon's overall GF Score™ is 70/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Haleon (HLN), the current Buyback Yield % is 2.06 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Haleon (HLN) Overvalued in 2026?
Based on GuruFocus' analysis, Haleon stock appears to be undervalued.
The current stock price of $9.75 is trading 0.5% below its estimated GF Value™ of $9.80.
GuruFocus considers Haleon to be Fairly Valued.
Key valuation signals for HLN:
Buyback Yield %: 2.06 (near median its 10-year median of 1.89)
GF Value™: $9.80 vs. price of $9.75 (0.5% below fair value)
No single metric tells the full story. See the HLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon's brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.
70GF Score
Get the complete analysis for HLN
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HLN has been successfully added to your 
